Translational Gastrointestinal Oncology and Metabolism

Our research focuses on two connected areas of translational medicine: upper gastrointestinal oncology and metabolic surgery. In both, we link clinical observations with molecular research to support more personalized patient care.

Upper Gastrointestinal Oncology

We study interactions between different intratumoral cell populations, including epithelial tumor cells and cancer-associated fibroblasts (CAFs). We investigate how these interactions contribute to disease progression, metastasis, and treatment resistance. To explore these mechanisms, we study heterogeneity within and between esophageal, gastroesophageal junction, and gastric adenocarcinomas and map the cellular organization of their tumor microenvironment. Using patient-derived organoids and tissue slice cultures, we test current chemo- and immunotherapies to assess treatment responses and investigate ways to target tumor escape mechanisms.

Metabolic and Bariatric Surgery Research

We analyze disease mechanisms and clinical and molecular biomarkers in obesity, MASLD, and MASH, with a focus on predicting surgical outcomes and understanding differences in tissue remodeling between patients. As surgeon-scientists, we combine clinical care with systematic collection of blood, tissue, and stool around surgery. By following long-term changes in the metabolome, lipid composition, microbiome, and immune cell profiles, we seek predictive markers and investigate systemic immune-mediated disease processes.

Across both research areas, we combine single-cell RNA sequencing, FACS-sorted transcriptomics, and spatial metabolomics with long-term clinical data to inform individualized clinical strategies.

About us

PD Dr. med. Patrick Sven Plum is a visceral surgeon and translational scientist specializing in upper gastrointestinal and metabolic surgery. He works at the Department of General, Visceral and Transplant Surgery in Tübingen, following earlier roles in surgery and research at the University Hospital Cologne and the University of Leipzig. His research combines clinical surgical data with molecular and spatial tissue profiling.

He uses single-cell RNA, FACS-sorted and CITE sequencing to study the tumor microenvironment of upper gastrointestinal adenocarcinomas and metabolic changes after bariatric surgery. His work includes cost-effective methods for analyzing clinical tissue samples, with the aim of improving diagnosis and treatment of cancer and metabolic disorders. His awards include the Walter Krienitz Prize, the Julius Springer Prize for Surgery, the DGAV Theodor Billroth Prize and the ESDE Best Abstract Award.

  • Deutsche Forschungsgemeinschaft (DFG) - Projektnummer: 264590883 Mehr erfahren
OGI Oncology
Cellular heterogeneity and tumor microenvironment of upper gastrointestinal adenocarcinomas
Metabolic Surgery
Longitudinal clinical and molecular profiling in bariatric and metabolic interventions
Spatial Multi-Omics
High-resolution transcriptomic tracking and systemic immunometabolic profiling

Selected Publications

  • 2026

    eGDR and gastrointestinal cancer mortality in the UK Biobank: a prospective cohort study

    Yang C, Plum PS, Ebert T, Köppe J, Gockel I, Thieme R. eGDR and gastrointestinal cancer mortality in the UK Biobank: a prospective cohort study. BMC Cancer. 2026 Sep 5;26(1):1060. doi: 10.1186/s12885-026-16931-1. PMID: 42701202; PMCID: PMC13545786. https://doi.org/10.1186/s12885-026-16931-1
  • 2026

    Gene expression adaptation of metastases to their host tissue

    Nagel L, Wenzel M, Hoppe S, Karimpour M, Plum PS, Hamoudi A, Jahan I, Schmitt S, Franitza M, Wahba R, Bludau M, Bruns CJ, Quaas A, Beyer A, Hillmer AM. Gene expression adaptation of metastases to their host tissue. iScience. 2026 Jul 21;29(8):116744. doi: 10.1016/j.isci.2026.116744. PMID: 42495525; PMCID: PMC13392873. https://doi.org/10.1016/j.isci.2026.116744
  • 2025

    Artificial neural networks as a prognostic tool using hyperspectral imaging on pretherapeutic histopathological specimens of esophageal adenocarcinoma

    Trifone CT, Maktabi M, Bischoff P, Schierle K, Niebisch S, Moulla Y, Plum PS, Jansen-Winkeln B, Gockel I, Thieme R. Artificial neural networks as a prognostic tool using hyperspectral imaging on pretherapeutic histopathological specimens of esophageal adenocarcinoma. J Cancer Res Clin Oncol. 2025 Oct 4;151(10):274. doi: 10.1007/s00432-025-06340-5. PMID: 41044268; PMCID: PMC12495013. https://doi.org/10.1007/s00432-025-06340-5
  • 2025

    Single-cell analysis of Barrett's esophagus and carcinoma reveals cell types conferring risk via genetic predisposition

    Wenzel MC, Dasmeh P, Plum PS, Giel AS, Hoppe S, Franitza M, Jonas C, Thieme R, Zhao Y, Heider D, Palles C, Fitzgerald RC, Bruns CJ, Buettner R, Quaas A, Gockel I, Maj C, Chon SH, Schumacher J, Hillmer AM. Single-cell analysis of Barrett's esophagus and carcinoma reveals cell types conferring risk via genetic predisposition. Cell Genom. 2025 Oct 8;5(10):100980. doi: 10.1016/j.xgen.2025.100980. Epub 2025 Sep 8. PMID: 40925382; PMCID: PMC12790991. https://doi.org/10.1016/j.xgen.2025.100980
  • 2025

    Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy

    Hoeppner J, Schmoor C, Brunner T, Bronsert P, Plum PS, Nimczewski F, Madarasz Z, Lordick F. Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy. J Clin Oncol. 2025 Nov 10;43(32):3451-3456. doi: 10.1200/JCO-25-00948. Epub 2025 Jul 9. PMID: 40632972. https://doi.org/10.1200/jco-25-00948
  • 2024

    Therapy-relevant MDM2 amplification in cholangiocarcinomas in Caucasian patients

    Lyu SI, Plum PS, Fretter C, Simon AG, Bedau T, Knipper K, Thomas MN, Stippel D, Wagner BJ, Bruns C, Waldschmidt D, Büttner R, Drebber U, Quaas A. Therapy-relevant MDM2 amplification in cholangiocarcinomas in Caucasian patients. Ther Adv Med Oncol. 2024 Nov 9;16:17588359241288123. doi: 10.1177/17588359241288123. PMID: 39525665; PMCID: PMC11550496. https://doi.org/10.1177/17588359241288123
  • 2024

    Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker

    Plum PS, Hess T, Bertrand D, Morgenstern I, Velazquez Camacho O, Jonas C, Alidousty C, Wagner B, Roessler S, Albrecht T, Becker J, Richartz V, Holz B, Hoppe S, Poh HM, Chia BKH, Chan CX, Pathiraja T, Teo AS, Marquardt JU, Khng A, Heise M, Fei Y, Thieme R, Klein S, Hong JH, Dima SO, Popescu I, Hoppe-Lotichius M, Buettner R, Lautem A, Otto G, Quaas A, Nagarajan N, Rozen S, Teh BT, Goeppert B, Drebber U, Lang H, Tan P, Gockel I, Schumacher J, Hillmer AM. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker. Clin Transl Med. 2024 Jun;14(6):e1723. doi: 10.1002/ctm2.1723. PMID: 38877653; PMCID: PMC11178519. https://doi.org/10.1002/ctm2.1723
  • 2023

    Extension of resection after positive intraoperative pathology during surgery for gastric and gastroesophageal junction adenocarcinoma: a retrospective cohort study

    Plum PS, Barutcu AG, Pamuk A, Mallmann C, Chon SH, Chiapponi C, Dübbers M, Hellmich M, Moenig SP, Quaas A, Hoelscher AH, Bruns CJ, Alakus H. Extension of resection after positive intraoperative pathology during surgery for gastric and gastroesophageal junction adenocarcinoma: a retrospective cohort study. Int J Surg. 2023 Aug 1;109(8):2324-2333. doi: 10.1097/JS9.0000000000000484. PMID: 37222663; PMCID: PMC10442120. https://doi.org/10.1097/js9.0000000000000484
  • 2023

    Predicting the HER2 status in oesophageal cancer from tissue microarrays using convolutional neural networks

    Pisula JI, Datta RR, Valdez LB, Avemarg JR, Jung JO, Plum P, Löser H, Lohneis P, Meuschke M, Dos Santos DP, Gebauer F, Quaas A, Walch A, Bruns CJ, Lawonn K, Popp FC, Bozek K. Predicting the HER2 status in oesophageal cancer from tissue microarrays using convolutional neural networks. Br J Cancer. 2023 Mar;128(7):1369-1376. doi: 10.1038/s41416-023-02143-y. Epub 2023 Jan 30. PMID: 36717673; PMCID: PMC10050393. https://doi.org/10.1038/s41416-023-02143-y
  • 2022

    Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus

    Hoppe S, Meder L, Gebauer F, Ullrich RT, Zander T, Hillmer AM, Buettner R, Plum P, Puppe J, Malter W, Quaas A. Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus. Cancers (Basel). 2022 Sep 30;14(19):4789. doi: 10.3390/cancers14194789. PMID: 36230712; PMCID: PMC9562858. https://doi.org/10.3390/cancers14194789
  • 2021

    Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center

    Quaas A, Rehkaemper J, Rueschoff J, Pamuk A, Zander T, Hillmer A, Siemanowski J, Wittig J, Buettner R, Plum P, Popp F, Gebauer F, Bruns CJ, Loeser H, Alakus H, Schoemig-Markiefka B. Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center. Front Oncol. 2021 Jul 22;11:569475. doi: 10.3389/fonc.2021.569475. PMID: 34367937; PMCID: PMC8343401. https://doi.org/10.3389/fonc.2021.569475
  • 2021

    Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy

    Thelen M, Wennhold K, Lehmann J, Garcia-Marquez M, Klein S, Kochen E, Lohneis P, Lechner A, Wagener-Ryczek S, Plum PS, Velazquez Camacho O, Pfister D, Dörr F, Heldwein M, Hekmat K, Beutner D, Klussmann JP, Thangarajah F, Ratiu D, Malter W, Merkelbach-Bruse S, Bruns CJ, Quaas A, von Bergwelt-Baildon M, Schlößer HA. Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. NPJ Precis Oncol. 2021 Jun 16;5(1):52. doi: 10.1038/s41698-021-00196-x. PMID: 34135436; PMCID: PMC8208982. https://doi.org/10.1038/s41698-021-00196-x
  • 2022

    Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma

    Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut. 2022 Jan;71(1):185-193. doi: 10.1136/gutjnl-2020-322493. Epub 2021 Jan 11. PMID: 33431577; PMCID: PMC8666816. https://doi.org/10.1136/gutjnl-2020-322493
  • 2021

    GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy

    Plum PS, Löser H, Zander T, Essakly A, Bruns CJ, Hillmer AM, Alakus H, Schröder W, Büttner R, Gebauer F, Quaas A. GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy. J Cancer Res Clin Oncol. 2021 Apr;147(4):1031-1040. doi: 10.1007/s00432-020-03486-2. Epub 2020 Dec 10. PMID: 33300112; PMCID: PMC7954758. https://doi.org/10.1007/s00432-020-03486-2
  • 2020

    Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer

    Zhou C, Fan N, Liu F, Fang N, Plum PS, Thieme R, Gockel I, Gromnitza S, Hillmer AM, Chon SH, Schlösser HA, Bruns CJ, Zhao Y. Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer. Cells. 2020 Jun 17;9(6):1481. doi: 10.3390/cells9061481. PMID: 32560537; PMCID: PMC7349233. https://doi.org/10.3390/cells9061481
  • 2020

    Cell type-specific transcriptomics of esophageal adenocarcinoma as a scalable alternative for single cell transcriptomics

    Krämer M, Plum PS, Velazquez Camacho O, Folz-Donahue K, Thelen M, Garcia-Marquez I, Wölwer C, Büsker S, Wittig J, Franitza M, Altmüller J, Löser H, Schlößer H, Büttner R, Schröder W, Bruns CJ, Alakus H, Quaas A, Chon SH, Hillmer AM. Cell type-specific transcriptomics of esophageal adenocarcinoma as a scalable alternative for single cell transcriptomics. Mol Oncol. 2020 Jun;14(6):1170-1184. doi: 10.1002/1878-0261.12680. Epub 2020 Apr 21. PMID: 32255255; PMCID: PMC7266280. https://doi.org/10.1002/1878-0261.12680
  • 2020

    Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data

    Hescheler DA, Plum PS, Zander T, Quaas A, Korenkov M, Gassa A, Michel M, Bruns CJ, Alakus H. Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data. Gastric Cancer. 2020 Jul;23(4):627-638. doi: 10.1007/s10120-020-01045-9. Epub 2020 Feb 27. PMID: 32107691; PMCID: PMC7305081. https://doi.org/10.1007/s10120-020-01045-9
  • 2019

    Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma

    Schiffmann LM, Göbel H, Löser H, Schorn F, Werthenbach JP, Fuchs HF, Plum PS, Bludau M, Zander T, Schröder W, Bruns CJ, Kashkar H, Quaas A, Gebauer F. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma. BMC Cancer. 2019 May 31;19(1):531. doi: 10.1186/s12885-019-5722-1. PMID: 31151416; PMCID: PMC6545033. https://doi.org/10.1186/s12885-019-5722-1
  • 2019

    HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma

    Plum PS, Gebauer F, Krämer M, Alakus H, Berlth F, Chon SH, Schiffmann L, Zander T, Büttner R, Hölscher AH, Bruns CJ, Quaas A, Loeser H. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC Cancer. 2019 Jan 8;19(1):38. doi: 10.1186/s12885-018-5242-4. PMID: 30621632; PMCID: PMC6325716. https://doi.org/10.1186/s12885-018-5242-4
  • 2018

    Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence

    Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence. Sci Rep. 2018 Oct 8;8(1):14941. doi: 10.1038/s41598-018-33027-4. PMID: 30297788; PMCID: PMC6175817. https://doi.org/10.1038/s41598-018-33027-4
  • 2015

    Both GLUT-1 and GLUT-14 are Independent Prognostic Factors in Gastric Adenocarcinoma

    Berlth F, Mönig S, Pinther B, Grimminger P, Maus M, Schlösser H, Plum P, Warnecke-Eberz U, Harismendy O, Drebber U, Bollschweiler E, Hölscher A, Alakus H. Both GLUT-1 and GLUT-14 are Independent Prognostic Factors in Gastric Adenocarcinoma. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S822-31. doi: 10.1245/s10434-015-4730-x. Epub 2015 Jul 17. PMID: 26183839. https://doi.org/10.1245/s10434-015-4730-x